UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063629
Receipt number R000072821
Scientific Title RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study
Date of disclosure of the study information 2026/11/16
Last modified on 2026/11/16 07:05:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study

Acronym

RAISE

Scientific Title

RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study

Scientific Title:Acronym

RAISE

Region

Japan


Condition

Condition

Systemic rheumatic diseases treated with anti-inflammatory and immunomodulatory agents

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to establish a multicenter registry using electronic health record data from patients with systemic rheumatic diseases and to continuously evaluate treatment patterns, clinical outcomes, and the safety of anti-inflammatory and immunomodulatory therapies in real-world clinical practice.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

All-cause mortality and causes of death

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients meeting all of the following criteria will be included in the analysis:
1. A history of outpatient visits to, or hospitalization under the primary or secondary care of, a rheumatology and connective tissue disease department at a participating institution.
2. A diagnosis of a systemic rheumatic disease, regardless of whether the relevant classification criteria are fulfilled.
3. Initiation of anti-inflammatory and immunomodulatory therapy for the purpose of controlling disease activity after the start of electronic health record operation at each participating institution.

Key exclusion criteria

Patients who meet either of the following criteria:

Patients who were not registered in this study and visited the study institution 15 or more days after initiation of anti-inflammatory or immunomodulatory treatment for disease activity control of systemic rheumatic diseases at another medical institution, and who meet either of the following conditions:
(a) Patients with no history of hospitalization in the Department of Rheumatology and Clinical Immunology (or equivalent department) at the study institution, and who had either three or fewer actual outpatient visit days in that department or an observation period of less than 100 days, with no occurrence of death or adverse events by the time of the last observation.

(b) Patients for whom the diagnostic evidence, date of treatment initiation, treatment details (including the history of anti-inflammatory or immunomodulatory drug use and the initial dose of glucocorticoids), or history of disease relapse cannot be confirmed from the provided medical records or other clinical information.

Target sample size

7500


Research contact person

Name of lead principal investigator

1st name Taio
Middle name
Last name Naniwa

Organization

Nagoya City University Hospital

Division name

Department of Rheumatology and Clinical Immunology / Department of Respiratory Medicine, Immunology and Allergology, Graduate School of Medical Sciences

Zip code

467-8602

Address

1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan

TEL

052-853-8216

Email

tnaniwa@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name Shinya
Middle name
Last name Tamechika

Organization

Nagoya City University Hospital

Division name

Department of Rheumatology and Clinical Immunology / Department of Respiratory Medicine, Immunology

Zip code

467-8602

Address

1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan

TEL

052-853-8216

Homepage URL


Email

s-tame@med.nagoya-cu.ac.jp


Sponsor or person

Institute

Nagoya City University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya City University Medical Research Institutional Review Board

Address

1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan

Tel

052-853-8348

Email

clinical_research@med.nagoya-cu.ac.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

60-26-0011

Org. issuing International ID_1

Nagoya City University Medical Research Institutional Review Board

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 16 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2026 Year 04 Month 14 Day

Date of IRB

2026 Year 04 Month 24 Day

Anticipated trial start date

2026 Year 04 Month 24 Day

Last follow-up date

2036 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Eligible patients will be identified using existing electronic medical records at each participating institution. Clinical data will be collected from medical records, medication and laboratory orders, and test results. Text data from medical records will also be used when necessary. After registration, data on patient characteristics, disease activity, treatments, laboratory findings, organ damage, disease relapse, and adverse events will be updated periodically for longitudinal follow-up. Patients will be classified into cohorts according to treatment details and the timing of treatment initiation. Real-world treatment patterns, clinical outcomes, and safety will be analyzed. No study-specific interventions, additional examinations, or biological sample collection will be performed.


Management information

Registered date

2026 Year 11 Month 14 Day

Last modified on

2026 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072821